Point72 Asia (Singapore) Pte. Ltd. Protalix Bio Therapeutics, Inc. Transaction History

Point72 Asia (Singapore) Pte. Ltd.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$1.88 - $2.69 $1,253 - $1,794	667 Added 1.25%	54,174 $139 Million
Q4 2024 Feb 14, 2025	BUY	$0.99 - $1.92 $6,369 - $12,353	6,434 Added 13.67%	53,507 $101 Million
Q3 2024 Nov 14, 2024	SELL	$0.9 - $1.17 $18,981 - $24,675	-21,090 Reduced 30.94%	47,073 $48 Million
Q2 2024 Aug 14, 2024	BUY	$1.1 - $1.32 $74,979 - $89,975	68,163 New	68,163 $79.8 Million

10.6M

23.6K

95.4K

Ticker PLX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,753,400
Market Cap $92.5M
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...

Get notified when there are updates to the investment portfolio of Point72 Asia (Singapore) Pte. Ltd., based on Form 13F filings with the SEC.

Stay updated on Point72 Asia (Singapore) Pte. Ltd. with notifications on news.